Massey scientists uncover process that could drive the majority of cancers
The gene p53 has been described as the “guardian of the genome” due to its prominent role in preventing genetic mutations. More than half of all cancers are thought to originate from p53 mutations or loss of function, and now a recent study by VCU Massey Cancer Center scientist Richard Moran, Ph.D., explains why.
Massey researcher awarded grant to develop treatment for metastatic cancer
VCU Massey Cancer Center researcher Paula Bos, Ph.D., was recently awarded a 2016 Metastatic Cancer Research Grant from METAvivor Research and Support Inc. The grant funding will support Bos in expanding her research on brain metastasis.
Clinical trial developed at Massey tests novel combination of chemotherapy and radiation therapy for the treatment of pancreatic cancer
A phase 1 clinical trial developed at VCU Massey Cancer Center is testing a combination of targeted therapy with standard chemotherapy and radiation given prior to surgery in patients with non-metastatic pancreatic cancer. Surgery is often the most effective treatment for pancreatic cancer, but in many cases it is not possible if the tumor has spread to other parts of the digestive system or nearby organs. Neoadjuvant therapy, or therapy prior to surgery, can help shrink tumors and make them operable.
The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
VCU scientists work to bring about a new treatment for rare childhood cancer
Neuroblastoma is a rare cancer that develops in very early forms of nerve cells in the embryo or fetus, and it accounts for the most pediatric deaths for any tumor outside of the brain. The most lethal form of this tumor is often associated with amplification of the gene MYCN, and now scientists at VCU Massey Cancer Center and the VCU Philips Institute for Oral Health Research may have developed a combination therapy that uses this gene to kill the cancer, instead of making it grow.